Remoxipride
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.

This is an excerpt from the article Remoxipride from the Wikipedia free encyclopedia. A list of authors is available at Wikipedia.
The article Remoxipride at en.wikipedia.org was accessed 542 times in the last 30 days. (as of: 11/05/2013)
Images on Remoxipride
Preview image:
Original:
Search results from Google and Bing
1
1
1
Remoxipride - Wikipedia, the free encyclopedia
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the  ...
en.wikipedia.org/wiki/Remoxipride
2
>30
2
DrugBank: Remoxipride (DB00409)
Jun 13, 2005 ... Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur.
www.drugbank.ca/drugs/DB00409
3
>30
3
Remoxipride hydrochloride Supplier | CAS 73220-03-8 | Tocris ...
View and buy high purity Remoxipride hydrochloride from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents.
www.tocris.com/dispprod.php?ItemId=1834
4
>30
4
Pharmacology of the atypical antipsychotic remoxipride, a dopamine ...
Remoxipride is a substituted benzamide that acts as a weak but very selective antagonist of dopamine D2 receptors. It was introduced by Astra (Roxiam) at the  ...
www.ncbi.nlm.nih.gov/pubmed/11607043
5
>30
5
Once-daily controlled release remoxipride is equieffective with twice ...
A controlled release (CR) formulation of Remoxipride (Roxiam(®), Astra) given once-daily was compared to immediate release (IR) Remoxipride given twice- daily, ...
www.ncbi.nlm.nih.gov/pubmed/22290842
6
>30
6
A long-term study of remoxipride in chronic schizophrenic patients.
The purpose of this study was to assess the tolerability and efficacy of 150-600 mg Remoxipride (predominantly a DA2 receptor antagonist) in an open long-term  ...
www.ncbi.nlm.nih.gov/pubmed/8447237
7
>30
7
Remoxipride - PubChem
Structure, classification, information, physical and chemical properties for Romoxipride, Remoxipridum [INN-Latin], Remoxiprida [INN-Spanish], FLA-731, ...
pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54477
8
>30
8
The atypical antipsychotic, remoxipride, blocks phencyclidine ...
The effect of various typical (haloperidol) and atypical (clozapine, raclopride, Remoxipride) antipsychotics on phencyclidine (PCP)-induced disruption of ...
www.ncbi.nlm.nih.gov/pubmed/7701046
9
>30
9
Pharmacokinetics of remoxipride controlled release and immediate ...
Single dose and steady-state pharmacokinetics of Remoxipride, a new antipsychotic drug, were compared after administration of a controlled release capsule ...
www.ncbi.nlm.nih.gov/pubmed/1974271
10
>30
10
Remoxipride Hydrochloride | CAS 73220-03-8 | Santa Cruz Biotech
Buy Remoxipride Hydrochloride (CAS 73220-03-8), a selective and potent D2RD agonist, from Santa Cruz. Molecular Formula: C16H23BrN2O3⋅HCl, MW: ...
www.scbt.com/datasheet-200410.html
Search results for "Remoxipride"
Google: approx. 32.300
Remoxipride in science
Once-daily controlled release remoxipride is equieffective with twice ...
Department of Psychiatry, St. James's University Hospital, Leeds LS9 7TF. A controlled release (CR) formulation of Remoxipride (Roxiam(®), Astra) given ...
Fatal intoxication by Remoxipride.
Department of Forensic Medicine, University of Helsinki, Finland. The case ... Remoxipride is a recently developed neuroleptic drug of the benzamide type.
Effects of remoxipride, an atypical antipsychotic, on cocaine self ...
Department of Pharmacology, University of Arizona, Tucson 85724, USA. Remoxipride, a selective D2-dopamine receptor antagonist with preferential activity for ...
Remoxipride in the treatment of levodopa-induced psychosis.
Neuropharmacology Clinic, Toronto Hospital, University of Toronto, Ontario, ... After 1 week of baseline observation, the patients received Remoxipride, 25 mg, ...
A double-blind multicentre study comparing remoxipride, controlled ...
Aug 23, 2007 ... A double-blind multicentre study comparing Remoxipride, controlled release formulation, with haloperidol in schizophrenia. B. Pflug1,*,; M.
Remoxipride - University of Rochester Medical Center
This graph shows the total number of publications written about "Remoxipride" by people in the URMC Research Network by year, and whether "Remoxipride" ...
Systemic and Direct Nose-to-Brain Transport Pharmacokinetic ...
The selective dopamine-D2 receptor antagonist Remoxipride was .... Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The ...
Remoxipride | Profiles RNS - Search - Thomas Jefferson University
"Remoxipride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged ...
[PDF]Remoxipride Remoxipride Remoxipride - Springer
der, Department of Neuroscience, The Johns Hopkins University School of ..... Remoxipride is a substituted benzamide of the same class as sui pi ride, and has  ...
A placebo controlled trial of remoxipride in the prevention of relapse ...
Of the remaining patients 19 were randomised to Remoxipride (150–300 mg daily ) .... Department of Therapeutics and Pharmacology, The Queen's University of ...
Books on the term Remoxipride
Psychiatric Side Effects of Prescription and ...
Psychiatric Side Effects of Prescription and ...
Thomas Markham Brown, Alan Stoudemire, 1998
General Dose-dependent neuropsychiatric side effects of Remoxipride therapy include insomnia (15%), fatigue (8%), tremor (6%-30%), somnolence (5%), rigidity (3%), akathisia (2%), dyskinesias (2%), hypokinesia (1%), and acute dystonia ...
Contemporary Issues in the Treatment of Schizophrenia
Contemporary Issues in the Treatment of Schizophrenia
Christian L. Shriqui, Henry A. Nasrallah, 1995
In general, Remoxipride has been excellently tolerated by patients. As a relatively specific dopamine D2 receptor blocker, it would be expected that Remoxipride would produce a relatively high incidence of EPS; however, this has not been ...
Interspecies Pharmacokinetic Scaling: Principles And Application of Allometric Scaling
Interspecies Pharmacokinetic Scaling: Principles And Application of Allometric Scaling
Iftekhar Mahmood, 2005
Pharmacokinetic allometric scaling is a very useful tool for the selection of first-in-human dose in drug development. This is the first book ever written on the interspecies pharmacokinetic scaling consists of 393 pages and is an ideal resource for pharmaceutical scientists, pre-clinical and clinical pharmacologists, physiologists, biochemists, to...
The New Pharmacotherapy of Schizophrenia
The New Pharmacotherapy of Schizophrenia
Alan Breier, 1996
Remoxipride Remoxipride is a specific D2-receptor antagonist, with preferential affinity for extrastriatal D2 receptors (Wadworth and Heel 1990). It has little affinity for serotonergic, muscarinic, oij noradrenergic, or histamine receptors ...
Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)
Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)
Michael S. Lidow, 2000
Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have few...
Atypical Antipsychotics
Atypical Antipsychotics
Bart A. Ellenbroek, Alexander Rudolf Cools, 2000
The substituted benzamide Remoxipride shares many of the properties of sulpiride. The results of animal experiments with Remoxipride suggested that this compound causes a preferential blockade of the mesolimbic DA- receptors [96].
CNS Neurotransmitters and Neuromodulators: Dopamine
CNS Neurotransmitters and Neuromodulators: Dopamine
Trevor W. Stone, 1996
CNS Neurotransmitters and Neuromodulators: Dopamine is an indispensable single-volume resource for any researcher involved with dopamine in the central nervous system (CNS). Part of the CNS Neurotransmitters and Neuromodulators Series, it is destined to be the definitive reference work on this topic. This book is comprised of independently authored...
Psychology of Time
Psychology of Time
Simon Grondin, 2008
profile of Remoxipride is that of a so-called ''atypical'' antipsychotic drug with a low potential for extrapyramidal side effects. An explanation for this relatively low potential for motor side effects seen with Remoxipride may be its much more ...
Development of Google searches


Blog posts on the term
Remoxipride
NMDA/Sigma Receptors and HPA Axis
The use of NMDA antagonists have been used by some as a means of countering habituation to the effects of stimulants and "re-balancing" one's HPA axis. This has been discussed at length in various threads, however, sigma receptors are often over looked, and rightfully so, as typical opiates or cocaine would likely cause more troubles than they resolve. However, there are a few other drugs that might have efficacy... Here's a few articles I ran across that I found interesting. Sigma
www.mindandmuscle.net/forum/showthread.php?t=39671
PLOS ONE: Effects of the Selective 5-HT7 Receptor Antagonist SB-269970 and Amisulpride on Ketamine-Induced Schizophrenia-like Deficits in Rats
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.
www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0066695
The Effect of Thiamine and Thiamine Pyrophosphate on Oxidative Liver Damage Induced in Rats with Cisplatin
BioMed Research International (formerly titled Journal of Biomedicine and Biotechnology) is a peer-reviewed, open access journal that publishes original research articles as well as review articles in several areas of life sciences. The journal’s Editorial Board is divided into the 55 subject areas included within the journal’s scope.
www.hindawi.com/journals/bmri/2013/783809/
A history of SSRIs | seroxat secrets...
Over the years I have collected a few interesting documents and I think it's just plain selfish to keep them to myself so I'm starting to share them with you. The one for download here - A History of SSRIs is exactly what it says it is... a history of SSRIs. You can read about…
seroxatsecrets.wordpress.com/2007/03/03/a-history-of-ssris/
Drug Articles Research References | The Camp Recovery Center - Bay Area Northern CA
Posted on June 1, 2011 by.
camprecovery.crchealth.com/articles/drug-articles-research-references/
ApHogee Protein Treatment NATURAL hair :D | rutisass
In one study of 299 patients with neuroleptic overdose, thioridazine was associated with a significantly greater incidence of prolonged QRS, prolonged QTc, and arrhythmia as compared to other neuroleptics [ 21 ]. Electrocardiographic abnormalities or obvious cardiotoxicity should be evident within several hours of overdose. Newer agents alter cardiac conduction less frequently but are not…
rutisass.wordpress.com/2012/12/16/aphogee-protein-treatment-natural-hair-d/
Psychiatry Kills Documented Proof Psychiatric Drugs Shorten Life Span / FLUORIDE – LUNATIC DRUG / FLUORIDE USED BY THE NAZI TO DISABLE, KILL IN THE DEATH CAMPS / FORCED STERALIZATION OF THE INNOCENT, …. – A MUST READ ESPECIALLY NOW !!! | Wesdancin
Psychiatry Kills Documented Proof Psychiatric Drugs Shorten Life Span Version 2.012m By Shemuwel Antoine Moser Also see: This and Thisfor information proving the USA is medicating people through their water supply. No longer is involuntary drugging only a concern to those locked away in an institution. "Laws quietly passed in 36 US states now allow…
wesdancin.wordpress.com/2011/12/20/psychiatry-kills-documented-proof-psychiatric-drugs-shorten-life-span-fluoride-lunatic-drug-fluoride-used-by-the-nazi-to-disable-kill-in-the-death-camps-forced-steralization-of-the-innocent-2/
12